Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer

Stoke Therapeutics Inc., a biotechnology company dedicated to restoring protein expression, has appointed Thomas McCauley, Ph.D., as Chief Scientific Officer.

“Our first investigational medicine, zorevunersen, has shown the potential to change the course of Dravet syndrome by addressing the underlying genetic cause of the disease,” said Ian F. Smith, CEO and Director of Stoke Therapeutics. “As we build on this proof-of-concept for our platform and expand our pipeline beyond Dravet, Tom’s leadership and deep translational expertise will help us identify and advance the best opportunities to turn novel science from our research organization into more life-changing medicines for patients.”

Experience

McCauley joins Stoke with over 25 years of experience leading high-performing R&D teams and translating early scientific discoveries into clinical programs that have delivered new medicines to people living with severe diseases. He brings extensive expertise in developing novel technology platforms and modalities across multiple therapeutic areas, including six years at Shire where he played a key role in the late-stage development and global approvals of multiple genetic medicines for rare diseases. In this new role, he will be responsible for leading Stoke’s scientific strategy and leveraging the Company’s proprietary RNA medicines platform to expand and advance its pipeline.

McCauley most recently served as the President and CEO of Neptune Bio, where he drove the company’s strategic vision and advanced therapeutic applications for its scientific platform. McCauley previously served as the Chief Scientific Officer at Omega Therapeutics, Macrolide Pharmaceuticals and Translate Bio, where he led the advancement of each company’s scientific platform and drug development capabilities. Earlier in his career, he held leadership and scientific roles at Shire, Inotek Pharmaceuticals, and Archemix Corp. He currently serves as a Scientific Advisor for multiple early-stage biotechnology companies in the RNA and genetic therapeutics space.

McCauley holds undergraduate and graduate degrees in Applied & Engineering Physics from Cornell University and received his Ph.D. in Physics from the University of Alabama at Birmingham.